BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
March 19, 2003
View Archived Issues
For $55M, OSI Gets Novantrone U.S. Cancer Rights From Serono
Serono SA signed a licensing agreement with OSI Pharmaceuticals Inc., granting OSI exclusive rights to market and promote Novantrone in the U.S. in its approved oncology indications. (BioWorld International)
Read More
OncoGenome Sciences Raises EUR14M For Cancer Diagnostics
Read More
New Drugs Could Flow From Bacterial Gene Cluster Variants
Read More
UroGene Second Round: EUR12M For Itself, Subsidiary Chrysalon
Read More
Riding Smallpox Contracts, Acambis Reports 2002 Profit
Read More
EU Worries More Biotechnology Companies Could Quit Europe
Read More
Entomed, Naeja Enter Two-Way Cancer, Infectious Diseases Deal
Read More
Potential OGS Buyers, CAT, Celltech, Jockey For Position
Read More
CellFactors Seeking £3.5M To Advance, Partner Skeletex
Read More
Products, Fundamentals Find Investor Favor In Down Market
Read More
Other News To Note
Read More